Synthesis and clinical evaluation of cyclotron-produced [68Ga]PSMA-11 and [18F]PSMA-1007 for prostate cancer imaging
[¹⁸F]PSMA-1007 provides significant advantages in production scalability and lesion detectability, particularly in skeletal and pelvic regions; however, its higher rate of benign uptake necessitates careful interpretation to avoid false positives. While both tracers are clinically effective, tracer selection should be guided by logistical feasibility, clinical context, and interpretive considerations.
Authors
- Muhammad Fakhrurazi Ahmad Fadzil (ORCID: https://orcid.org/0000-0003-4675-3078)
- Noratikah Mat Ail
- Zarif Ashhar (ORCID: https://orcid.org/0000-0001-5057-4705)
- Mazurin Mahamood
- Mohamad Aminudin Said (ORCID: https://orcid.org/0000-0001-6137-5373)
- Zaitulhusna Md Safee
- May Aziz
- Muhammad Adib Abdul Onny (ORCID: https://orcid.org/0000-0001-8544-8119)
- Mohd Fazrin Mohd Rohani (ORCID: https://orcid.org/0000-0002-8450-0170)
- Nik Muhammad Fitri Nik Afinde
- Nor Idayu Razali
- Chen Siew Ng
- Roslan Abd. Rahman
- N. Ali (ORCID: https://orcid.org/0000-0002-5838-3126)
- Hamdi Noor
- Nurul Ain Yaacob
- Tharmasilen Selvarajoo
Institutions
- Universiti Sains Malaysia (MY)
- Hospital Kuala Lumpur (MY)
- Sultanah Aminah Hospital (MY)
Publication Details
- Journal
- Nuclear Medicine Communications
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1097/mnm.0000000000002009
- Citations
- 3
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 4.08